公开(公告)号：US20170349661A1

公开(公告)日：2017-12-07

申请号：US15501526

申请日：2015-08-03

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun LIU ,  Sandra ZURAWSKI ,  SangKon OH ,  Shino HANABUCHI ,  Haruyuki FUJITA ,  Hideki UENO ,  Patrick BLANCO ,  Hyemee JOO

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell- (Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US20250121048A1

公开(公告)日：2025-04-17

申请号：US18990184

申请日：2024-12-20

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/00 ,  A61K39/395 ,  C07K14/005 ,  C07K16/28 ,  C12N7/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20250025548A1

公开(公告)日：2025-01-23

申请号：US18710734

申请日：2022-11-16

Applicant: Institut National de la Santé et de la Recherche Médicale ,  Assistance Publique - Hopitaux de Paris ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne

Inventor： Yves LEVY ,  Gérard ZURAWSKI ,  Sandra ZURAWSKI ,  Mireille CENTLIVRE ,  Christine LACABARATZ ,  Sylvain CARDINAUD ,  Mathieu SURENAUD

IPC: A61K39/215 ,  A61P31/14 ,  C07K16/28 ,  C12N7/00

Abstract: Sarbecoviruses (lineage B of genus Betacoronavirus) have caused two major outbreaks during the past two decades: SARS-CoV in 2003, and SARS-CoV-2 from 2019. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. Therefore, universal vaccines against this class of viruses are key to ending the current pandemic, but also for preventing additional emergent variations and future outbreaks of SARS-like viruses that are continuously found from nature reservoirs. Now, the inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated or fused to a protein N polypeptide of SAR-CoV-2 and the light chain is fused to a RBD polypeptide. In particular, the inventors show that said antibody could elicit immune responses against Sarbecoviruses.

公开(公告)号：US20210308242A1

公开(公告)日：2021-10-07

申请号：US17301704

申请日：2021-04-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard ZURAWSKI ,  Jacques F. Banchereau ,  Anne-Laure FLAMAR ,  Peter KLUCAR ,  Keiko AKAGAWA ,  Sandra ZURAWSKI ,  SangKon OH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/435

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20210268097A1

公开(公告)日：2021-09-02

申请号：US17194779

申请日：2021-03-08

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20200316191A1

公开(公告)日：2020-10-08

申请号：US16946390

申请日：2020-06-19

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicate) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

Inventor： Yves LEVY ,  Gerard ZURAWSKI ,  Sandra ZURAWSKI ,  Anne-Laure FLAMAR

IPC: A61K39/21 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00 ,  C07K16/28 ,  C07K16/10 ,  A61K39/12

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US20200101152A1

公开(公告)日：2020-04-02

申请号：US16708787

申请日：2019-12-10

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

Inventor： Yves LEVY ,  Gerard ZURAWSKI ,  Sandra ZURAWSKI ,  Anne-Laure FLAMAR

IPC: A61K39/21 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00 ,  C07K16/28 ,  C07K16/10 ,  A61K39/12

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).